Tamer I. Khayal - Aug 5, 2022 Form 4 Insider Report for TransMedics Group, Inc. (TMDX)

Role
Chief Commercial Officer
Signature
By: /s/ Stephen Gordon, Attorney-in-Fact
Stock symbol
TMDX
Transactions as of
Aug 5, 2022
Transactions value $
-$880,300
Form type
4
Date filed
8/9/2022, 06:00 PM
Previous filing
Aug 1, 2022
Next filing
Aug 25, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMDX Common Stock Options Exercise $22.1K +10K +769.23% $2.21* 11.3K Aug 5, 2022 Direct F1
transaction TMDX Common Stock Sale -$452K -10K -88.5% $45.16 1.3K Aug 5, 2022 Direct F1
transaction TMDX Common Stock Sale -$451K -10K -22.33% $45.08 34.8K Aug 5, 2022 By the Khayal Family 2021 Irrevocable Trust F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMDX Stock Option (Right to Buy) Options Exercise $0 -10K -24.36% $0.00 31.1K Aug 5, 2022 Common Stock 10K $2.21 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $45.00 to $45.40, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The option is fully vested.